- Advertisement -
- Advertisement -
- Advertisement -
- Advertisement -
Crizanlizumab is thought to cut visits to A&E by 40% for patients with the blood disorder.
- Advertisement -
Crizanlizumab is thought to cut visits to A&E by 40% for patients with the blood disorder.